News

Sartar was selected to present at the Anglonordic Life Science Conference held at the County Hall in London on 5th May 2022. The event gathers European investors and R&D companies from the Nordics and the UK to connect with each other. In addition to the presenting companies, the program focused on the current trends in […]

Sartar participated the NOME Annual Meeting on 23rd Nov 2021 in Copenhagen, meeting mentors and other life science and medtech startups. NOME is an elite Nordic Mentoring Program that matches selected Nordic startups with highly skilled professionals to help them reach their goals and technology milestones. Sartar was selected to the program last June and has […]

Sartar Therapeutics was selected to NOME (Nordic Mentor Network for Entrepreneurship), an elite Nordic Mentoring program that connects most promising life science startups with highly skilled relevant professionals to help them reach their goals and technology milestones. We had our first mentoring session with lots of valuable insights and are eager to continue the journey […]

We are proud to inform that the national innovation funding body Business Finland has granted R&D funding for Sartar Therapeutics. This R&D loan will allow us to advance the development of our product SAR001 towards clinical trials. We consider this positive decision as a significant credit for our technology for the treatment of soft tissue sarcomas.

We are happy to announce Mikael Maksimow has joined our team as a COO. Welcome Mikael! Mikael has broad experience in drug development from innovations to international clinical trials. His experience in advancing start-up companies will be a great addition to our small but efficient team. 

Targeting phosphodiesterase 3A: discovery of a promising cancer therapy in Drug Target Review describes the science behind Sartar’s new cancer therapy, outlining emerging evidence that PDE3A protein-targeting compounds may induce sarcoma cell death by acting as a molecular glue between PDE3A and Schlafen 12 proteins. Link to original article

We are happy to be selected as one of the rising star companies at Nordic Life Science Invest Days. Link to NLS Days website

Sartar was selected among close to 100 other companies who also applied to the competition. “I think the six selected cases are very interesting and definitely represent those who have the highest potential and the best traction”, says Peter Birk, Accelerace. Read original article

We warmly wecome Katja to the company! She is a passionate innovator with solid background in pharmaceutics, product development and startups.